FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer

New personalised medicine helped people in Phase III study live longer, compared to standard treatment
Source: Roche Media News - Category: Pharmaceuticals Source Type: news